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Radiat Oncol Biol Phys. 2010;78:S15.NTARYThe best that surgery has to offerThomas A. D’Amico, MDThe treatment of patients with stage I lung cancer con-
tinues to be examined through decades of controversy:lobectomy versus sublobar resection, minimally invasive
strategies versus open approaches, and most recently the
use of nonsurgical interventions versus resection. Each of
these debates pivots on the competing principles of optimiz-
ing oncologic efficacy while minimizing invasiveness and
complications. Although the Lung Cancer Study Group es-
tablished lobectomy as the standard of care for clinical stage
I lung cancer,1 those findings are being challenged by trials
demonstrating equivalent results with segmentectomy in
selected patients2 and currently being tested again in
a prospective, randomized trial (Cancer and Leukemia




Commentary D’Amicosuperiority of thoracoscopic lobectomy compared with
open approaches.4,5
The role of surgery in the management of patients with
clinical stage I lung cancer is now being challenged by the
emergence of 2 nonsurgical interventions: radiofrequency
ablation (RFA) and stereotactic body radiation therapy
(SBRT). RFA has been demonstrated to be safe and effective
in selected patients with lung cancer in several studies and is
under evaluation now in a recently completed multi-
institutional prospective phase II study: American College
of Surgeons Oncology Group [ACOSOG] Z4033.6 In addi-
tion, SBRT has been used with success in the management
of clinical stage I lung cancer, most notably in a prospective
phase II study (Radiation Therapy Oncology Group 0236),7
and it is currently being comparedwith sublobar resection in
a prospective, randomized trial: ACOSOG Z4099.8
As all practitioners involved in the multidisciplinary
management of lung cancer await the results of this study, a re-
cent comparative analysis of completed clinical trials of RFA,
SBRT, and sublobar resectionmay improve our understanding
of these 3 competing techniques.9 The stated purposes of this
analysis were to compare selection criteria and to assess the
short-term outcomes of the 3 studies. The power of this anal-
ysis is limited by several factors, including the size of theRFA
study (ACOSOG Z4033; n ¼ 51)6 and the size of the SBRT
study (Radiation Therapy Oncology Group 0236; n ¼ 55).7
The complications that may have arisen from the biopsy pro-
cedures in the nonsurgical trialswas not assessed.Another im-
portant limiting factor is the allowance of wedge resections
(more than two thirds of patients) and thoracotomy (more
than one thirdofpatients) in the sublobar resection trial (ACO-
SOG Z4032),10 strategies that proved to be inferior to
anatomic and thoracoscopic approaches in this patient popula-
tion.2,4,5 In addition, comparisons between nonsurgical
techniques and resection are limited by the use of clinical,
as opposed to pathologic, staging. It is also difficult to assess
patient selection in the nonsurgical trials—why patients
were turned down for surgery. Pulmonary function tests are
relatively objective, but measuring frailty and other
comorbid conditions is more complex. Finally, although the
assessment of short-term outcomes is important, the absence
of long-term oncologic outcomes does limit the conclusions
of any comparative analysis.
Although there were some statistically significant differ-
ences among the 3 trials in pretreatment clinical parameters
(age and pulmonary function), there are 4 important results
that are elucidated in this analysis.9 First, 29.3% of patients
in the sublobar resection trial were upstaged (clinical stagevs
pathologic stage) after surgery. Although there were some
differences in the baseline characteristics of the 3 trials,
one must assume that the assignment of clinical stage under-
estimates the pathologic stage in 25% to 30% of patients
treated byRFA and SBRT.Although the ongoing prospective
randomized trial comparing SBRT and sublobar resection700 The Journal of Thoracic and Cardiovascular Surgwill more definitively address this question when the inci-
dences of local and regional recurrences between the 2 tech-
niques can be compared, the issue of clinical understaging
and assignment of interventional therapy remains of concern.
Second, the propensity-matched analysis demonstrates
no difference in the development of significant adverse
events (3þ) after SBRT and sublobar resection. Although
the complication profile after resection of lung is well un-
derstood,4,5 it may be erroneously assumed that SBRT—
described as noninvasive—is associated with a lower
procedural risk. Although the number of post-therapy
deaths was higher in the sublobar resection group, the rate
of 3þ adverse events was not significantly different. Accu-
rate risk assessment will certainly be important in the selec-
tion of therapy for patients with marginal pulmonary
function or other comorbid conditions.
Also of note, the post-treatment decline in pulmonary
function was not significantly different in patients treated
with SBRT or sublobar resection. Although it may be diffi-
cult to draw conclusions in an analysis of patients treated
with 2 different modalities in 2 separate clinical trials, the
possible assumption by clinicians evaluating patients with
clinical stage I lung cancer and marginal pulmonary func-
tion that SBRT is associated with higher preservation of pul-
monary function may be incorrect. Again, this question will
be better addressed in the ongoing prospective trial.
Finally, it must also be pointed out that approximately
13% of patients in the sublobar resection trial had no docu-
mented lymph node staging.9 I believe it is safe to assume
that a significant fraction of patients in this trial also did
not have the minimum of 3 mediastinal lymph nodes
assessed, as is recommended by current clinical guidelines.11
That, in conjunction with the fact that approximately two
thirds of the patients underwent wedge resection as opposed
to segmentectomy and approximately one third of patients
underwent resection via thoracotomy as opposed to thoraco-
scopy,6 describes a therapeutic surgical strategy that is subop-
timal andmay prove to be inferior to SBRTin the randomized
trial. This ongoing trial may define how patients with clinical
stage IAcancerswill be treated in the future, a population that
is likely to grow as lung cancer screening becomes more
prevalent. These patients may not be receiving the ideal ther-
apy in the future if surgeons do not recognize and practice the
best that surgery has to offer in optimizing oncologic efficacy
while minimizing invasiveness and complications.References
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